Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MST1R | Q04912 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 4/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL105274 | 1.00 | MET (0.39) | METMAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL16660463 | 0.91 | MST1R (0.41) | METMAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL16660462 | 0.82 | MAPT (0.37) | METMAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL16660464 | 0.82 | MAPT (0.37) | METMAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL171881 | 0.81 | MST1R (0.50) | METMST1RKDRNTRK1KIT | |
| SCHEMBL3864631 | 0.78 | MET (0.46) | METMST1RKDRNTRK1KIT | |
| SCHEMBL103974 | 0.77 | HDAC3 (0.37) | ALDH1A1POLBSMN1; SMN2MEN1LMNA | |
| SCHEMBL3575098 | 0.76 | MET (0.45) | METMAPTPOLBSMN1; SMN2NPSR1 | |
| SCHEMBL107202 | 0.76 | MST1R (0.51) | METMST1RKDRNTRK1KIT | |
| SCHEMBL107201 | 0.76 | MST1R (0.51) | METMST1RKDRNTRK1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426108-B1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC (CA) | 2016-08-10 | — | — | EP | disclosed |
| US-8907091-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-20130310564-A1 | Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors | METHYLGENE INC. (CA) | 2013-11-21 | — | — | US | disclosed |
| US-8569503-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2013-10-29 | — | — | US | disclosed |
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | Mirati Therapeutics, Inc. | 2012-04-19 | — | — | US | disclosed |
| EP-2426108-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MethylGene Inc. (CA) | 2012-03-07 | — | — | EP | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | MAP3K19, MAP3K9, MAP4K2 | MET 1062/4885MAPT 1952/4885ALDH1A1 3152/4885 |
| US-20130310564-A1 | Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors | MAP3K19, MAP3K15, MAP3K9 | MET 916/4885MAPT 1835/4885ALDH1A1 3373/4885 |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | MET 1062/4885MAPT 1952/4885ALDH1A1 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.